Amgen's Imdelltra Plus Imfinzi Cuts Death Risk 58% in Lung Cancer Trial
Amgen's drug Imdelltra, combined with AstraZeneca's Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, reduced the risk of death by 58% and raised median survival to 21.1 months, according to a trial presented at the European Society for Medical Oncology Congress in Madrid.
2newsrooms
2articles
26 hoursrunning
Oct 26first seen
Ask Scout
Scout answers questions about this story using only the coverage below.
Coverage over time
Articles
| Oct 27, 8:00 AM | washingtonexaminer.com | mRNA shouldn’t have a party affiliation |
| Oct 26, 5:40 AM | qz.com | Amgen's cancer drug combo cut death risk by 58% in lung cancer trial |